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Abstract
Previously, we demonstrated that mitochondrial bioenergetic deficits preceded Alzheimer’s disease (AD) pathology in the
female triple-transgenic AD (3xTgAD) mouse model. In parallel, 3xTgAD mice exhibited elevated expression of ketogenic
markers, indicating a compensatory mechanism for energy production in brain. This compensatory response to generate an
alternative fuel source was temporary and diminished with disease progression. To determine whether this compensatory
alternative fuel system could be sustained, we investigated the impact of 2-deoxy-D-glucose (2-DG), a compound known to
induce ketogenesis, on bioenergetic function and AD pathology burden in brain. 6-month-old female 3xTgAD mice were
fed either a regular diet (AIN-93G) or a diet containing 0.04% 2-DG for 7 weeks. 2-DG diet significantly increased serum
ketone body level and brain expression of enzymes required for ketone body metabolism. The 2-DG-induced maintenance
of mitochondrial bioenergetics was paralleled by simultaneous reduction in oxidative stress. Further, 2-DG treated mice
exhibited a significant reduction of both amyloid precursor protein (APP) and amyloid beta (Ab) oligomers, which was
paralleled by significantly increased a-secretase and decreased c-secretase expression, indicating that 2-DG induced a shift
towards a non-amyloidogenic pathway. In addition, 2-DG increased expression of genes involved in Ab clearance pathways,
degradation, sequestering, and transport. Concomitant with increased bioenergetic capacity and reduced b-amyloid
burden, 2-DG significantly increased expression of neurotrophic growth factors, BDNF and NGF. Results of these analyses
demonstrate that dietary 2-DG treatment increased ketogenesis and ketone metabolism, enhanced mitochondrial
bioenergetic capacity, reduced b-amyloid generation and increased mechanisms of b-amyloid clearance. Further, these data
link bioenergetic capacity with b-amyloid generation and demonstrate that b-amyloid burden was dynamic and reversible,
as 2-DG reduced activation of the amyloidogenic pathway and increased mechanisms of b-amyloid clearance. Collectively,
these data provide preclinical evidence for dietary 2-DG as a disease-modifying intervention to delay progression of
bioenergetic deficits in brain and associated b-amyloid burden.
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Introduction
The fundamental role of mitochondria in cellular bioenergetics
and survival has been well established [1,2,3]. In addition,
mitochondrial dysfunction has been proposed as a key regulator
in the pathogenesis of neurodegenerative disorders, including
Alzheimer’s disease (AD) [1,4,5,6]. We previously demonstrated
that mitochondrial bioenergetic deficits precede the development
of AD pathology in the female triple-transgenic Alzheimer’s mouse
model (3xTgAD) [7], and were further exacerbated with AD
progression [8,9]. Consistent with these basic science findings,
multiple clinical observations also report antecedent decline in
cerebral glucose utilization decades prior to the diagnosis of AD
[10,11,12]. Further, in clinical and preclinical analyses of AD
brains, a decline in glucose-supported energy production has been
observed, as evidenced by a decrease in the expression of glycolytic
enzymes coupled to a decrease in the activity of the pyruvate
dehydrogenase (PDH) complex [7,13].
Alteration in the brain metabolic profile of AD is associated with
a concomitant metabolism of ketone bodies to compensate for the
decline in glucose-driven ATP generation [14,15]. In young con-
trols, there is a 100:0 ratio of glucose utilization relative to other
substrates. In contrast, incipient AD patients exhibited a 2:1 ratio in
glucose utilization relative to other substrates compared to a 29:1
ratio in healthy elderly controls [16]. Consistent with these clinical
observations, we have demonstrated that in the female 3xTgAD
mouse model, pre-pathological decrease in PDH expression and
mitochondrial bioenergeticswereparalleledbyincreased expression
of succinyl-CoA:3-ketoacid coenzyme A transferase (SCOT) at a
young age (3 months), indicating early activation of ketogenic
pathways to compensate for compromised PDH capacity, thus
providing alternative sources of acetyl-CoA, and consequently
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generation. However, this compensatory pathway was temporary
and diminished with disease progression [7,17].
Targeting disease stage-specific phenotypes of brain metabolism
provides a potential therapeutic strategy to alleviate bioenergetic
deficits to delay disease progression. Under bioenergetic crisis,
ketone bodies can be used as an auxiliary and alternative fuel for
brain metabolism [18]. Utilization of ketone body-rich diets for
multiple neurological conditions has been associated with lower
risk of neurodegenerative diseases [19,20]. 2-deoxy-D-glucose (2-
DG) is a glucose analog with the 2-hydroxyl group replaced by
hydrogen. Due to the structural similarity between 2-DG and
glucose, 2-DG is transported by glucose transporters into the cell
where it binds to, but cannot be phosphorylated by, hexokinase
thereby disrupting further glycolysis [21]. Because 2-DG compet-
itively blocks glucose metabolism, 2-DG induces a compensatory
rise in alternative substrates, primarily ketone bodies by the liver.
By activating an alternative energetic pathway in brain, 2-DG
treatment promotes neuron survival in preclinical rodent models
of Parkinson’s and ischemia [22,23].
In the current study, we sought to investigate the therapeutic
potential of 2-DG to sustain and promote ketogenesis, to maintain
this alternative mitochondrial bioenergetic pathway, and to
decrease b-amyloid burden. The experimental model utilized
dietary exposure of 2-DG (0.04% 2-DG) in 6-month-old female
3xTgAD mice when intra-neuronal b-amyloid is detectable in the
subiculum, hippocampus and amygdala [7,24] and when bioen-
ergetic deficits are apparent [7,24]. Results presented herein
demonstrate that compared to the control diet, a 7-week-dietary
intervention of 2-DG significantly induced ketogenesis, sustained
mitochondrial bioenergetic function, and reduced Ab pathology.
Results
Ketone bodies sustain mitochondrial respiration in vitro
in neurons and mixed glia
While the normal brain exclusively relies on glucose for energy
production [1,25], under long-term starvation or certain disease
conditions, the brain can use alternative substrates, such as ketone
bodies, for ATP generation [18,20,26]. Ketone bodies are mainly
synthesized in the liver through fatty acid oxidation and are well
documented to serve as alternative energy substrates for the heart,
muscle, and brain. Further, ketogenic pathways have been
demonstrated to exist in astrocytes [20,27].
To investigate whether neurons and mixed glia can use
alternative substrates, we assessed mitochondrial respiration using
vehicle control (ctrl), pyruvate or the ketone bodies, acetoacetate
and b-hydroxybutyrate. The addition of substrates alone did not
increase basal oxygen consumption rates (OCR) in neurons or
mixed glia. However, following the addition of a mitochondrial
uncoupler, FCCP, which mimics maximal energy-demanding
situations, all substrates supported maximal respiration relative to
vehicle control, with pyruvate yielding the highest OCR value and
acetoacetate and b-hydroxybutyrate generating a moderate in-
crease in OCR (Fig. 1A&B). These data indicate that despite the
preferenceforglucose/pyruvatesubstrates,bothneuronsandmixed
glia are capable of using ketone bodies to meet energy demand.
2-DG induced ketogenesis in vivo in female 3xTgAD mice
To verify that 2-DG promoted ketogenesis in the 3xTgAD
mouse model in vivo, we investigated the impact of dietary 2-DG
on level of ketone bodies in the serum. A 7-week exposure of
0.04% 2-DG diet induced a significant increase in serum ketone
body (b-hydroxybutyrate) level (Fig. 2C, P,0.05). This increase
was paralleled by a significant decline in serum glucose level
(Fig. 2B, P,0.05). Consistent with the decline in serum glucose
and rise in serum ketone bodies, 2-DG induced a moderate but
steady decline in body weight which reached statistical significance
at week 6 and 7 (Fig. 2A, P,0.05).
2-DG diet sustained mitochondrial bioenergetic function,
reduced mitochondrial Ab load, and suppressed
oxidative stress
Mitochondrial dysfunction and in particular deficits in mito-
chondrial glucose-driven bioenergetics, are associated with AD
Figure 1. Utilization of ketone bodies as alternative fuel
substrates in neurons and mixed glia. Primary hippocampal
neurons from day 18 (E18) embryos of female Sprague-Dawley rats
were cultured in Neurobasal medium + B27 supplement for 10 days
prior to experiment. Mixed glia from day 18 (E18) embryos of female
Sprague-Dawley rats were cultured in growth media (DMEM:F12
(1:1)+10% FBS). Primary Oxygen consumption rate (OCR) was deter-
mined using the Seahorse XF-24 Metabolic Flux analyzer. Vertical lines
indicate time of addition of substrates and mitochondrial inhibitors.
Substrates include vehicle control (Ctrl), pyruvate, acetoacetate and b-
hydroxybutyrate. Mitochondrial inhibitors are oligomycin (5 mM) and
FCCP (1 mM). A&B, utilization of ketone bodies (acetoacetate and b-
hydroxybutyrate) in neurons and mixed glia, respectively (*, P,0.05
compared to Ctrl, n=5 wells per group).
doi:10.1371/journal.pone.0021788.g001
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are converted to acetyl-CoA by two key mitochondrial enzymes,
succinyl-CoA:3-ketoacid CoA transferase (SCOT) and acetyl-CoA
acetyltransferase 1 (ACAT1). Through this pathway, ketone bodies
can substitute for glucose/pyruvate as an alternative energy
substrate. Induction of ketogenesis by 2-DG could provide ketone
bodies to relieve the bioenergetic crisis. Exposure to 2-DG diet for
7 weeks increased the expression of both ketogenic pathway
enzymes, SCOT and ACAT1 (Fig. 3A, P,0.05).
a-ketoglutarate dehydrogenase, a key enzyme in the tricarboxylic
acid(TCA)cycle that generatesNADHrequired forATPgeneration
is documented to be significantly decreased in AD brain. Indicative
of the bioenergetic efficacy of the 2-DG diet, expression of
mitochondrial a-ketoglutarate dehydrogenase (aKGDH) was signif-
icantly increased (Fig. 3A, P,0.05). Consistent with a shift to the
ketogenic pathway, PDH was not regulated by 2-DG treatment
(Fig. 3A).
Mitochondrial accumulation of Ab has been demonstrated in
multiple AD mouse models [7,30]. Ab accumulation within
mitochondria is associated with mitochondrial dysfunction,
including decreased oxidative phosphorylation (OXPHOS) and
increased oxidative stress [30]. To investigate the impact of dietary
2-DG treatment on mitochondrial b-amyloid, we determined the
expression of both APP and 16 kD Ab in isolated crude brain
mitochondrial preparations. 2-DG significantly reduced both
mitochondrial APP and the 16 kD mitochondrial Ab oligomer
level (Fig. 3B, P,0.05).
Inefficiency of mitochondrial respiration is associated with
oxidative stress, which can adversely impact both mitochondrial
function, bioenergetics, and cell survival [31]. To determine the
impact of 2-DG on oxidative stress, we investigated indicators of
oxidative stress, including the expression of stress proteins, the
anti-oxidant capacity, and lipid peroxidation status. 2-DG diet
significantly reduced the expression of stress response proteins,
including MnSOD, PrdxV, and Hsp60 (Fig. 3C, P,0.05). In
addition to protein expression, total SOD and MnSOD enzyme
activities were significantly decreased in the 2-DG group (Fig. 3D,
P,0.05). To determine the overall oxidative status of the brain, we
assessed lipid peroxidation and total anti-oxidant capacity from
cortical tissue homogenates. 2-DG treated mice exhibited
significantly lower lipid peroxidation (Fig. 3E, P,0.05), whereas
the total anti-oxidant capacity was slightly though not significantly
increased (Fig. 3D).
2-DG induced reduction in b-amyloid burden through
activation of the non-amyloidogenic pathway in 3xTgAD
mice
To investigate the impact of 2-DG diet on Ab pathology, we
assessed the expression level of amyloid precursor protein (APP)
and multiple Ab oligomers, including the 56 kD, 27 kD, and
16 kD Ab species in the hippocampal homogenate samples.
Consistent with 2-DG induced reduction in mitochondrial Ab
load, 2-DG significantly reduced the expression of APP and each
of the Ab oligomers investigated (Fig. 4A, P,0.05). In contrast, 2-
DG significantly increased the a-secretase cleavage product of
APP (sAPPa) (Fig. 4A, P,0.05). To confirm protein expression
outcomes, we conducted immunofluorescent labeling of brain
sections derived from both the control (Ctrl) and 2-DG diet treated
groups. Consistent with protein expression profiles, 6E10 im-
munolabeling of Abindicated a qualitative reduction in Abspecies
in the hippocampal CA1 region by 2-DG (Fig. 4B). In parallel with
the reduction in Ab labeling, there was a qualitative reduction in
activated microglia as indicated in reduced signal in Iba1
immunofluorescence (Fig. 4B).
The simultaneous increase in sAPPa and decrease in APP and
Aboligomers indicate a shift from an amyloidogenic pathway
towards a non-amyloidogenic pathway by 2-DG. To confirm these
findings, we determined the expression level of the three key
enzymes in APP processing, the b-secretase enzyme (BACE1), the
a-secretase enzyme (ADAM metallopeptidase domain 10, AD-
AM10), and thec-secretase enzyme (Presenilin 1, PS1). Consistent
with the changes in APP, sAPPa and Aboligomers, 2-DG induced
a significant decrease in PS1 expression and a significant increase
in ADAM10 protein expression (Fig. 4C, P,0.05), indicating a
simultaneous increase in non-amyloidogenic pathways and a
Figure 2. Induction of ketogenesis by 2-DG in vivo. 3xTgAD female
mice at 6 months of age were randomly assigned to either Ctrl (AIN93G)
or 2-DG (AIN93G+0.04% 2-DG) group. Body weight was monitored once
per week. Percent of Change is defined as (BW0n-BW00)/ BW00*100%
(00, week 0 prior to the beginning of the treatment; 0n, weeks of duration
on designated diet). Animals were sacrificed upon completion of 7 weeks
of treatment. Serum samples were collected for glucose and ketone
body level measurement. A, 2-DG induced body weight loss (*, P,0.05
compared to Ctrl, data points represent mean value 6 SEM). B, 2-DG
induced significant decline in serum glucose level (*, P,0.05 compared
to Ctrl, bars represent mean value 6 SEM). C, 2-DG induced significant
increase in serum ketone body level (*, P,0.05 compared to Ctrl, bars
represent mean b-hydroxybutyrate level 6 SEM).
doi:10.1371/journal.pone.0021788.g002
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burden.
2-DG did not impact Tau hyperphosphorylation in
3xTgAD mice
At 6 to 8 months of age in the 3xTgAD mouse model,
neurofibrillary tangles are not apparent whereas hyperphosphory-
lated Tau (pTau) is detectable. 2-DG treatment did not sig-
nificantly affect either pTau protein expression (Fig. 5A) or
immunofluorescent pTau (CP13) signal (Fig. 5B).
2-DG regulated AD and bioenergetic related gene
expression
To determine whether the effects of 2-DG observed at the
protein level are supported by gene expression and to extend our
understanding to a broader system level, we conducted target
driven Low Density gene Arrays (LDA) to assess of the impact of
2-DG on gene expression related to Alzheimer’s pathology and
mitochondrial bioenergetics. Compared to the Ctrl diet, 2-DG
induced significant change in the expression of 28 genes, which
were categorized into the following groups: APP processing, Ab
Figure 3. 2-DG sustained mitochondrial bioenergetic function, reduced mitochondrial Ab load, and suppressed oxidative stress.
Mitochondrial samples of both the Ctrl and 2-DG group were analyzed for protein levels of 1) bioenergetic enzymes, including SCOT, ACAT1, OGDH,
and PDH; 2) amyloid species, including APP and 16 kD Ab oligomer; 3) oxidative stress markers, including MnSOD, Prdx V, and Hsp60 by western blot.
Cortical tissue homogenates from both the Ctrl and 2-DG groups were analyzed for total SOD and MnSOD activity, total anti-oxidant capacity, and
lipid peroxidation. A, 2-DG significantly increased protein expression of enzymes involved in ketone utilization, including SCOT, ACAT1 and OGDH; In
contrast, PDH was not changed by 2-DG (*, P,0.05 compared to Ctrl, bars represent mean value 6 SEM); B, 2-DG significantly decreased
mitochondrial APP and 16 kD Ab oligomer level (*, P,0.05 compared to Ctrl, bars represent mean value 6 SEM); C, 2-DG significantly decreased
protein expression of oxidative stress response markers, including MnSOD, Prdx V, and Hsp60 (*, P,0.05 compared to Ctrl, bars represent mean value
6 SEM); D, 2-DG significantly decreased both SOD and MnSOD activity while the total anti-oxidant capacity was slightly increased (*, P,0.05
compared to Ctrl, bars represent mean value 6 SEM); E, 2-DG significantly decreased lipid peroxidation (*, P,0.05 compared to Ctrl, bars represent
mean value 6 SEM).
doi:10.1371/journal.pone.0021788.g003
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ketogenesis, and Alzheimer’s pathway related (Table 1). Consistent
with our findings, 2-DG treatment significantly increased the
mRNA level of genes involved in non-amyloidogenic pathways,
including ADAM metallopeptidase domain 10 and 17 (ADAM
10&17). In addition, genes involved in amyloid degradation
including metalloproteinase2 (MMP2) and insulin degrading
enzyme (IDE) as well as genes involved in amyloid clearance
including ATP-binding cassette transporter 1 (ABCA1) and
transthyretin (TTR) were significantly up-regulated by 2-DG.
The simultaneous up-regulation of genes promoting the non-
amyloidogenic and Ab clearance pathways would be predicted to
synergize to reduce Ab generation and accumulation in the brain,
which is consistent with our protein expression findings described
above. Genes that were down-regulated by 2-DG treatment
include acetylcholinesterase (ACHE), which would be predicted to
sustain or increase acetylecholine level in hippocampus, glutathi-
one reductase (GSR), which is consistent with our findings of a
reduction in markers of oxidative stress, and translocase of outer
mitochondrial membrane 40 (TOMM40), which is consistent with
the decline in mitochondrial Ab burden (Table 1).
2-DG induced up-regulation of neurotrophic factors
The increase in bioenergetic capacity and decrease in b-amyloid
burden would be expected to result in increased neural viability.
To test this hypothesis, we investigated the expression of
neurotrophic growth factors including brain-derived neurotrophic
factor (BDNF), basic fibroblast growth factor (FGF2), and nerve
growth factor (NGF). We also investigated the expression and
distribution of activity-regulated cytoskeleton-associated protein
Figure 4. 2-DG reduced amyloid pathology through activation of the non-amyloidogenic pathway in 3xTgAD mice. Hippocampal
homogenate samples from both the Ctrl and 2-DG groups were analyzed for protein levels of APP, multiple forms of Ab oligomer (56 kD, 27 kD,
16 kD), sAPPa fragment, ADAM10, BACE1, and PS-1 by western blot. Brain sections were stained for amyloid species (6E10) and microglia marker (Iba
I). A, 2-DG induced significant decrease in APP, 56 kD, 27 kD and 16 kD Ab oligomer protein level. In contrast, sAPPalevel was significantly increased
by 2-DG (*, P,0.05 compared to Ctrl, bars represent mean values 6 SEM); B, immunofluorescent labeling of amyloid with 6E10 antibody in the
hippocampal CA1 region. Image i–iv: lower magnification, scale bar: 100 mm; images v–viii, higher magnification, scale bar: 20 mm. Images i, ii, v, and
vi: 6E10 only, Images iii, iv, vii, and viii: 6E10 with microglia marker IbaI labeling and DAPI; C, 2-DG treatment significantly increased expression of a
secretase ADAM10 protein levels. In contrast, c secretase PS-1 protein level was significantly decreased by 2-DG.b secretase was not changed by 2-DG
(*, P,0.05 compared to Ctrl, bars represent mean value 6 SEM).
doi:10.1371/journal.pone.0021788.g004
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2-DG induced a significant increase in expression of BDNF
homodimers and NGF (Fig. 6A, P,0.05). While total Arc protein
expression did not change with 2-DG treatment (Fig. 6A), the
immunoreactive distribution of Arc changed from a randomly
scattered pattern of distribution to a clustered organization within
neuronal processes (Fig. 6B, indicated by the arrows). The
clustered distribution of Arc is suggestive of association with the
translational machinery within neural processes, which has been
observed in multiple models of learning of memory and induced
by BNDF [32,33].
Figure 5. 2-DG did not regulate Tau hyperphosphorylation.
Hippocampal homogenate samples from both the Ctrl and 2-DG
groups were analyzed for protein levels of pTau (PHF13) by western
blot. Brain sections were stained for pTau (CP13) and total Tau (Tau 46).
A, 2-DG did not affect pTau protein level; B, immunofluorescent labeling
of pTau (CP13) and total Tau (Tau 46) in the hippocampal CA1 region.
Images i–iv: lower magnification, Scale bar: 100 mm; images v–viii,
higher magnification, scale bar: 20 mm. Images i, ii, v, and vi: pTau
(CP13) + DAPI; images iii, iv, vii, and viii: total Tau (Tau46) + DAPI.
doi:10.1371/journal.pone.0021788.g005
Table 1. 2-DG induced change in gene expression involved in
amyloid production/clearance, mitochondrial function and
Alzheimer’s disease.
Functional
Category Fold Change P Value
APP Processing
Adam17-Mm00456428_m1 1.4926 0.0034
Adam10-Mm00545742_m1 1.1599 0.0242
Psenen-Mm00727761_s1 1.2052 0.0291
Amyloid Degradation/Clearance
Abca1-Mm00442646_m1 1.5071 0.0016
Mmp2-Mm00439508_m1 3.5924 0.0019
Ace-Mm00802048_m1 6.0105 0.0049
Ttr-Mm00443267_m1 30.4869 0.0068
Ide-Mm00473077_m1 1.2194 0.0124
Mitochondrial bioenergetics and ketogenesis
Slc2a1-Mm00441480_m1 1.3059 5.00E-04
Ucp2-Mm00627599_m1 2.0263 0.001
Hadh2-Mm00840109_m1 1.1549 0.0032
Acadl-Mm00599660_m1 1.3591 0.0044
Slc25a20-Mm00451571_m1 1.1783 0.0125
Cpt2-Mm00487202_m1 1.6721 0.0043
Acadm-Mm00431611_m1 1.2031 0.0435
Gsr-Mm00439151_m1 0.7344 0.0168
Tomm40-Mm00444138_m1 0.783 0.0459
Alzheimer’s related
Casp6-Mm00438053_m1 1.5359 0.0011
Pla2g5-Mm00448161_m1 6.4006 0.0033
Pld1-Mm01289339_m1 1.2964 0.0084
Ache-Mm00477275_m1 0.7976 0.0112
A2m-Mm00558642_m1 3.7326 0.0128
Il1b-Mm00434228_m1 3.4138 0.0137
Aplp2-Mm00507819_m1 1.6861 0.0188
Picalm-Mm00525455_m1 1.1798 0.022
Cr1l-Mm00785297_s1 1.2961 0.0221
Ctsc-Mm00515580_m1 1.7215 0.0262
Cdc2a-Mm00772472_m1 1.9644 0.0316
RNA samples isolated from hippocampal tissues of both the Ctrl and 2-DG
groups were analyzed for gene expression with LDA mouse Alzheimer’s and
customized mitochondrial array. Genes that were significantly regulated by 2-
DG (P,0.05 compared to Ctrl) were categorized into 4 different functional
groups: APP processing; amyloid degradation and clearance; ketogenesis and
mitochondrial function; and Alzheimer’s related. Data is presented as fold
change relative to the Ctrl group with the corresponding p value listed for each
individual gene.
doi:10.1371/journal.pone.0021788.t001
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In this study, we demonstrated that ketone bodies, including
acetoacetate and b-hydroxybutyrate, sustained mitochondrial
respiration as alternative fuel source in vitro in both neurons and
mixed glia. We further provided in vivo evidence from both
protein/enzyme analyses and gene expression profile that 2-DG
diet induced ketogenesis, increased mitochondrial enzymes
involved in ketone utilization for energy production, activated
non-amyloidogenic pathway, reduced Ab pathology, increased
neurotrophin expression, and reduced oxidative stress. These
findings suggest a potential therapeutic strategy to sustain
Figure 6. 2-DG increased protein expression of neurotrophic growth factors. Hippocampal homogenate samples from both the Ctrl and 2-
DG groups were analyzed for protein levels of BDNF, NGF, FGF2, and Arc. Brain sections were stained for Arc distribution in the hippocampal CA1
region. A, 2-DG induced significant increase in BDNF homodimer and NGF protein levels whereas FGF2 and Arc protein level remained unchanged
(*, P,0.05 compared to Ctrl, bars represent mean values 6 SEM); B, immunofluorescent labeling of Arc protein, upper panel, Arc immunofluorescent
labeling in neuronal processes; lower panel, Arc immunofluorescent labeling in peri-nuclear regions (arrows indicates clustered arrangement of Arc
immunolabeling in the neuronal processes, scale: 40 mm).
doi:10.1371/journal.pone.0021788.g006
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the AD brain.
Mitochondrial bioenergetic deficits have been demonstrated to
be closely associated with the pathogenesis of AD [4,7]. The
decline in mitochondrial bioenergetics induces a metabolic crisis
that activates a cascade of neurotoxic outcomes, including Ab
over-production and increase in oxidative stress, which eventually
lead to loss of synaptic functions and neuronal death [34,35].
Recent brain imaging studies in humans have demonstrated that
select regions of the brain exhibit elevated aerobic glycolysis.
Further, these same regions are most vulnerable to development of
AD pathology [36,37]. An interesting finding from these studies
was the disassociation between high levels of aerobic glycolysis and
oxygen consumption, the indicator of mitochondrial OXPHOS.
The increase in glycolysis relative to mitochondrial OXPHOS is
indicative of a disruption of coordinated glucose metabolism, most
likely due to limited pyruvate dehydrogenase (PDH) capacity as
PDH is the link between aerobic glycolysis and mitochondrial
OXPHOS. We have previously demonstrated that PDH is among
the first bioenergetic enzymes to be compromised prior to
appearance of AD pathology in the 3xTgAD mouse model [7].
The deficits in PDH capacity can be compensated through
utilization of a PDH independent alternative fuel, such as ketone
bodies, to generate acetyl-CoA for ATP production. In the current
study, 2-DG diet increased supplyof ketone bodies, up-regulated key
enzymes (SCOT and ACAT1) involved in ketone body utilization
and theTCAcycle.Promotingandsustainingtheketogenicpathway
by 2-DG diet prevented further decline in mitochondrial bioener-
getics, decreased oxidative stress, and reduced Ab pathology. Data
from this study corroborate that mitochondrial bioenergetics plays a
pivotal role in AD pathogenesis and that prevention or delaying the
decline in mitochondrial bioenergetic function may serve as a
therapeutic strategy for AD prevention or treatment.
In addition to mitochondrial bioenergetics, oxidative stress is
another important pathogenic factor in AD. Exhaustion of the anti-
oxidant system and increased oxidative damage of cellular compo-
nents have been reported in both AD patients and animal models
[31]. Compared to the control diet, 2-DG induced significant
reduction of stress response protein expression, including MnSOD,
PrdxV, and Hsp60. The decrease in stress response proteins/
enzymes was likely a secondary response to the reduction in oxidative
insults associated with Ab burden. This postulate is further supported
by 2-DG induced reduction in lipid peroxidation. Reduction in
oxidative damage by 2-DG contributed to the synergistic benefits
elicited by 2-DG to sustain mitochondrial bioenergetics and reduce
Ab pathology.
Amyloid b, a pathological hallmark of AD, is produced through
sequential cleavage of APP by bandc secretase. In contrast,
activation of a secretase leads to non-amyloidogenic processing of
APP and generation of truncated nontoxic sAPPa fragment [38].
The competition between a and b secretase pathways provides a
therapeutic target to reduce generation of Ab and prevent
activation of downstream neurotoxic cascades. Dietary 2-DG
induced a shift towards the non-amyloidogenic a-secretase
pathway by increasing the expression of the a-secretase enzyme
ADAM10, while decreasing the expression of c-secretase enzyme,
PS1. In addition, gene expression analyses indicated that 2-DG
activated multiple mechanisms of Ab clearance, including up-
regulation of Ab degrading enyzmes (IDE, ACE, and MMP2),
induction of cholesterol tracking pathway (ABCA1), and Ab
sequestration (TTR). Systemic reduction of both APP and Ab
oligomer species by 2-DG treatment was also observed in isolated
mitochondrial fractions. Dietary 2-DG treatment induced coordi-
nation of reduction in Ab generation and activation of Ab
clearance provided maximal benefit to relieve Ab associated
mitochondrial deficits and to prevent further development of Ab
pathology. Reduction in Ab load has been demonstrated to
correlate with improved cognitive function in multiple AD mouse
models [39,40,41]. In this vein, the anti-amyloidogenic benefits of
2-DG would be predicted to improve cognitive function in the 2-
DG treatment group. Further assessment of the impact of a 2-DG
intervention on cognitive function will corroborate this postulate
and is currently underway.
At 8 months of age when these animals were sacrificed, there was
no evidence for neurofibrillary tangles in the 3xTgAD mouse brain
whereas hyperphosphorylated Tau was apparent. Despite the
significant reduction of Ab pathology, 2-DG did not alter Tau
hyperphosphorylation. In the 3xTgAD mouse model, Tau pathol-
ogy has been demonstrated to follow Ab pathology [24]. The
disparity between reduction of Ab pathology and unchanged Tau
hyperphosphorylation observed in this study can be bridged by
considering that 2-DG could inhibits protein glycosylation [42].
Previous studies have demonstrated that competitive glycosylation of
Tau prevents Tau hyperphosphorylation [42]. Curiously, immuno-
fluorescent labeling for total Tau revealed a qualitative increase in
total Tau protein in the 2DG treated mice (Fig. 5B), suggesting an
expanded pool of Tau protein for cellular trafficking in the 2-DG
treated animals.
In addition to the bioenergetic benefits of 2-DG, mild weight
loss occurred in the mouse group treated with 2-DG, suggesting a
potential neurotrophic mechanism of 2-DG via caloric restriction.
Caloric restriction has been demonstrated to activate multiple
neuroprotective benefits and reduces Ab pathology in various AD
mouse models [43,44,45]. Further, caloric restriction has been
demonstrated to up-regulate expression of neurotrophic factors
such as BDNF [46,47,48], which was also achieved by dietary 2-
DG administration in the current study. In fact, it has been
suggested that the neuroprotective efficacy of both caloric
restriction and ketogenic diet can be partially mediated by ketone
bodies [49]. Yet, in this study, differences in mechanisms of action
between 2-DG and caloric restriction emerged. Caloric restric-
tion has been widely documented to increase expression of
stress-response genes, such as Manganese Superoxide Dismutase
(MnSOD) and heat shock proteins (HSPs)[50,51], whereas in this
study we observed a significant decrease in MnSOD expression
and activity and a decrease in Hsp60 expression, via a mechanism
different to that of caloric restriction and is more likely mediated
through direct reduction in mitochondrial generation of free
radicals [49]. These data indicate that 2-DG activates a unique
pattern of neuroprotective mechanisms that include components
that mediate benefits of both ketogenic diets and caloric restriction
to maintain mitochondrial bioenergetic function, reduce Ab
pathology and diminish neurotoxic insults.
Alzheimer’s is a neurodegenerative disease with a complex and
progressive pathological phenotype characterized first by hypome-
tabolism and impaired synaptic functionand followed by pathological
burden. The progressive and multifaceted degenerative phenotype of
Alzheimer’s suggests that successful treatment strategies need to be
equally multi-faceted and stage specific. Results of this study -
generated in a mouse model of genetically determined Alzheimer’s
disease- indicate that (a) dietary 2-DG treatment sustained and
enhanced mitochondrial bioenergetic capacity, thereby indicating
that ketone body metabolism can support neuronal function; (b)
intracellular b-amyloid burden was dynamic and reversible, as 2-DG
treatment reduced activation of the amyloidogenic pathway and
increased mechanisms of b-amyloid clearance, and (c) provide
preclinical evidence for dietary 2-DG as a disease-modifying
intervention to delay progression of bioenergetic deficits in brain
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been investigated in multiple preclinical and clinical studies
[52,53,54,55,56,57]. While most of the preclinical and clinical studies
demonstrated a relative safe profile of 2-DG when used at reasonable
doses,long-termchronicadministrationofhighdosesof2-DG,which
were 10 or more -fold higher than that used in our study, are
associated with adverse effects [58]. Although we did not observe
adverse effects in the 3xTgAD mice for the dosage and duration of 2-
DG investigated in the current study, it will be critical to establish
dose optimization of 2-DG to achieve maximal benefits and safety for
long-term chronic exposure. While the extent to which this
intervention is applicable to age-associated Alzheimer’s disease
remains to be determined, findings from the current study suggest
a novel dietary strategy to target brain bioenergetic function to
achieve pleiotropic benefits.
Materials and Methods
Animal Treatments and Ethics
All rodent experiments were performed following National
Institutes of Health guidelines on use of laboratory animals and an
approved protocol (protocol number: 10217) by the University of
Southern California Institutional Animal Care and Use Commit-
tee. The presented study has been approved by the University of
Southern California Institutional Animal Care and Use Commit-
tee (Ethics Committee).
Transgenic Mice
Colonies of 3xTgAD and nonTg mouse strain (C57BL6/129S;
Gift from Dr. Frank Laferla, University of California, Irvine) [24]
were bred and maintained at the University of Southern California
(Los Angeles, CA). Mice were housed on 12 h light/dark cycles
and provided ad libitum access to food and water. The
characterization of amyloid and Tau pathologies, as well as
synaptic dysfunction in this line of mice has been described
previously [24] and confirmed in our laboratory. Mice were
genotyped routinely to confirm the purity of the colony. To ensure
the stability of AD-like phenotype in the 3xTgAD mouse colony,
we performed routine immunohistochemical assays every three to
four generations. Only offspring from breeders that exhibit stable
AD pathology were randomized into the study.
In vitro Cell Culture and Seahorse XF-24 Metabolic Flux
Analysis
Primary hippocampal neurons from day 18 (E18) embryos of
female Sprague-Dawley rats were cultured on Seahorse XF-24
plates at a density of 50,000 cells/well. Neurons were grown in
Neurobasal Medium +B27 supplement for 10 days prior to
experiment. Mixed glia from day 18 (E18) embryos of female
Sprague-Dawley rats were cultured in T75 flasks and grown in
growth media (DMEM:F12 (1:1) +10% FBS). 24 hour prior to the
experiment, mixed Glia were trypsinized and seeded onto
Seahorse XF-24 plates at a density of 50,000 cells/well in growth
media. To investigate the potential of neurons and mixed glia to
use alternative fuel source (ketone bodies) other than glucose/
pyruvate, on the day of metabolic flux analysis, cells were changed
to unbuffered KHB (Krebs Henseleit Buffer, 111 mM NaCl,
4.7 mM KCl, 2 mM MgSO4, 1.2 mM Na2HPO4, 2.5 mM
glucose, and 0.5 mM Carnitine, pH 7.4) and incubated at 37uC
in a non-CO2 incubator for 1 h. All medium and injection
reagents were adjusted to pH 7.4 on the day of assay. Three
baseline measurements of oxygen consumption rate (OCR) were
taken before sequential injection of substrates and mitochondrial
inhibitors. Three readings were taken following each addition of
mitochondrial inhibitor prior to injection of the subsequent
inhibitors. The substrates used were vehicle control (Ctrl), ketones
including acetoacetate and b-hydroxybutyrate, and pyruvate,
respectively. The mitochondrial inhibitors used were oligomycin
(5 mM), FCCP (1 mM), and rotenone (1 mM). OCR was automat-
ically calculated and recorded by the Seahorse XF-24 software.
After the assays, plates were saved and protein readings were
measured for each well in order to confirm equal cell numbers
per well.
In vivo Experimental Design
To investigate the impact of 2-DG on mitochondrial func-
tion and Alzheimer’s pathology, 6-month-old female 3xTg-AD
mice were randomly assigned to either the control (Ctrl) diet
(AIN93G, Harlan Laboratories, CA) group or the 2-DG diet
(AIN93G+0.04% 2-DG, Harlan Laboratories, CA) group, n=16
per group. Mice were on the Ctrl or 2-DG diet for 7 weeks. Mouse
body weight was monitored once per week till the completion of
the study. Upon completion of the treatment, mice were sacrificed;
tissues were harvested, processed, and stored for later analyses.
Brain Tissue Preparation and Collection
Upon completion of the study, mice were sacrificed. Serum was
collected and stored at -80uC till use. Briefly, 0.5 ml of blood was
collected from each animal. Blood samples were allowed to clot at
RT for 30 min and then centrifuged at 2200 x g for 10 min.
Brains were perfused with pre-chilled PBS buffer (pH 7.2).
Cerebellum and brain stem were removed prior to further
dissection. For both the Ctrl and 2-DG group, eight mice were
designated from immunohistochemical analysis, of which the right
hemisphere was immersion fixed in 4% paraformaldehyde for
48 h and then stored in 4uC in PBS/1% sodium azide until use.
The left hemisphere was quickly harvested and processed for crude
mitochondrial isolation. Brains from the other eight mice in each
group were quickly dissected and hippocampal tissue from the left
hemisphere were harvested stored for RNA isolation and gene
Low Density Array (LDA) analyses; hippocampal tissue form the
right hemisphere were harvested and processed for western blot
analysis. Cortical tissues were harvested and processed for
subsequent enzyme activity, anti-oxidant capacity and lipid
peroxidation assays.
RNA isolation and Protein Extraction
Total RNA was isolated from the designated hippocampal
tissues using the RNeasy Kit (Qiagen, Valencia, CA) following the
manufacturer’s instruction. The quality and quantity of RNA
samples were determined using the Experion RNA analysis kit
(Bio-Rad, Hercules, CA). RNA samples were reverse-transcribed
to cDNA using the High capacity cDNA reverse transcription kit
(Applied Biosystems, Foster City, CA) following the manufaturer’s
instructions and stored at 280uC for gene array analysis. For
hippocampal homogenate, protein samples were extracted from
designated hippocampal tissues using the Tissue Protein Extract
Reagent (T-PER, Pierce, Rockford, IL) following the manufac-
turer’s protocol. Protein concentrations were determined by using
the BCA protein assay kit (Pierce, Rockford, IL).
Gene Expression Array Analysis
Mouse Alzheimer’s low density array (LDA) and customized
mitochondrial array was purchased from Applied Biosystems.
LDA array analyses were performed following the manufacturer’s
instruction and analyzed by RQ manager and Data Assist software
provided by the manufacturer.
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For immunohistochemistry studies, fixed hemispheres were
coronally sectioned at 30 mm, and then processed for immuno-
histochemistry using a standard protocol. Briefly, every 12
th
section was blocked (1 h at RT, PBS with 5% goat serum and
0.3% trinton x-100), immunolabeled using antibody directed
against Ab for (6E10, Covance, 1:1000 dilution 4uC overnight),
anti-IBA for microglia staining (Chemicon, Ramona, CA, 1:1000
dilution 4uC overnight), anti-pTau for pTau staining (CP13,
1:1000, Gift from Dr. Peter Davies, Albert Einstein College of
Medicine), anti-total Tau (Tau46, 1:500, Cell Signaling, Danvers,
MA), and anti-Arc for Arc staining (Arc antibody, Abcam, 1:500
Cambridge, MA) followed by washing and secondary antibody
Fluorescein goat anti-mouse (1:500, Chemicon, Ramona, CA, 1 h
at RT) and/or Cy3 conjugated goat anti-rabbit (1:1000,
Chemicon, Ramona, CA, 1 h at RT). Sections were mounted
with anti-fade mounting medium with DAPI (Vector Laboratories,
Burlingame, CA). Antigen unmasking treatment, consisting of
5 min rinse in 99% formic acid was performed to enhance Ab
immunoreactivity (IR). Fluorescent images were taken using
a fluorescent microscope, normalized and analyzed with the
slide book software (Intelligent Imaging Innovations Inc, Santa
Monica, CA).
Mitochondrial Preparation
Crude brain mitochondria were isolated from the designated
hemisphere following our previously established protocol [59] with
minor adaptation. Briefly, the hemisphere was rapidly minced and
homogenized at 4uC in mitochondrial isolation buffer (MIB)
(PH 7.4), containing sucrose (320 mM), EDTA (1 mM), Tris-HCl
(10 mM), and Calbiochem’s Protease Inhibitor Cocktail Set I
(AEBSF-HCl 500 mM, aprotonin 150 nM, E-64 1 mM, EDTA
disodium 500 mM, leupeptin hemisulfate 1 mM). Single-brain
homogenates were then centrifuged at 1500 X g for 5 min. The
pellet was resuspended in MIB, rehomogenized, and centrifuged
again at 1500 X g for 5 min. The postnuclear supernatants from
both centrifugations were combined, and were pelleted by
centrifugation at 21,000 X g for 10 min. The resulting
mitochondrial pellet was resuspended in 15% Percoll made in
MIB and centrifuged at 31,000 X g for 10 minutes to remove most
of the fatty acid contents. The resulting crude mitochondrial pellet
was resuspended in MIB and stored at stored at 280uC for later
protein and enzymatic assays.
Western Blot Analysis
Equal amounts of proteins (20 mg/well) were loaded in each
well of a 12% SDS-PAGE gel, electrophoresed with a Tris/glycine
running buffer, and transferred to a 0.45 mm pore size
polyvinylidene difluoride (PVDF) membrane and immunobloted
with 6E10 antibody (1:1000, Covance, Princeton, NJ), sAPPa
antibody (1:500, Covance, Princeton, NJ), PHF13/pTau antibody
(1:500, Covance, Princeton, NJ), PDH E1 alpha antibody (1:1000,
Mitosciences, Eugene, OR), ADAM10 antibody (1:500, Millipore,
Temecula, CA), PS-1 antibody (1:1000, Millipore, Temecula, CA),
BACE1 antibody (1:500, Covance, Princeton, NJ), FGF-2
antibody (1:200, Millipore, Temecula, CA), NGFb antibody
(1:500, Millipore, Temecula, CA) and BDNF antibody (1:200,
Chemicon, Ramona, CA), Arc antibody (1:500, Proteintech,
Chicago, IL), OGDH antibody (1:500, Proteintech, Chicago, IL),
SCOT Antibody (1:100, Santa Cruz, Santa Cruz, CA), ACAT1
antibody (1:500, Proteintech, Chicago, IL), MnSOD antibody
(1:1000, BD Biosciences, San Diego, CA), PrdxV antibody (1:200,
BD Biosciences, San Diego, CA), Hsp60 antibody (1:500,
Millipore, Temecula, CA), b-actin antibody (1:5000, Chemicon,
Ramona, CA), and porin/VDAC antibody (1:500, Cell Signaling,
Danvers, MA). Mitochondrial Ab oligomer (16 KD) level was
determined in isolated mitochondrial samples (20 mg/well) and
blotted by specific Anti-Ab monoclonal antibody (6E10, 1:1000,
Covance, Princeton, NJ). HRP-conjugated anti-rabbit antibody
and HRP-anti-mouse antibody (Vector Laboratories, Burlingame,
CA) were used as secondary antibodies. Immunoreactive bands
were visualized by Pierce SuperSignal Chemiluminescent Sub-
strates (Thermo Scientific) and captured by Molecular Imager
ChemiDoc XRS System (Bio-Rad, Hercules, CA). All band
intensities were quantified using Un-Scan-it software (Silk
Scientific, Orem, UT).
Serum Glucose and Ketone Body Assay
Serum glucose level was measured using the glucose assay kit
(Cayman Chemicals, Ann Arbor, MI) following the manufactur-
er’s instruction. Serum ketone body level was measured using the
LiquidColor b-hydroxybutyrate assay kit (Stanbio, Boerne, Tx)
following the manufacturer’s instruction.
Enzyme Activity and Total Anti-oxidant Assay
Total SOD and MnSOD activity was measured in cerebral
cortex tissue homogenates using the SOD activity assay kit
(Cayman Chemicals, Ann Arbor, MI) following the manufactur-
er’s instruction. Total anti-oxidant was measured in cerebral
cortex tissue homogenates using the total anti-oxidant assay
(Cayman Chemicals, Ann Arbor, MI) following the manufactur-
er’s instruction.
Lipid Peroxidation Assay
Lipid peroxidation of the cortical and hippocampal samples
from both the Ctrl and 2-DG groups were determined by assessing
the levels of Thiobarbituric Acid Reactive Substances (TBARS)
using the TBARS assay kit (Cayman Chemicals, Ann Arbor, MI)
following the manufacturer’s instruction.
Statistics. Statistically significant differences between the Ctrl
and 2-DG groups were determined by student t-test analysis.
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